1-2 of 2
H. Eirik Haarberg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

Free
Tomoko Smyth, Kim H.T. Paraiso, Keisha Hearn, Ana M. Rodriguez-Lopez, Joanne M. Munck, H. Eirik Haarberg, Vernon K. Sondak, Neil T. Thompson, Mohammad Azab, John F. Lyons, Keiran S.M. Smalley, Nicola G. Wallis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (12): 2793–2804.
https://doi.org/10.1158/1535-7163.MCT-14-0452
Published: 04 December 2014
View article titled, Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models
Open the PDF for Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models in another window
Journal Articles

Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma

Free
H. Eirik Haarberg, Kim H.T. Paraiso, Elizabeth Wood, Vito W. Rebecca, Vernon K. Sondak, John M. Koomen, Keiran S.M. Smalley
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 901–912.
https://doi.org/10.1158/1535-7163.MCT-12-1003
Published: 09 June 2013
View article titled, Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma
Open the PDF for Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma in another window
Includes: Supplementary data